Workflow
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
ZACKS·2025-10-06 22:51

Key Takeaways Genmab shares jumped 21.9% in a month on plans to acquire Merus for 8billionincash.Theacquisitionaddspetosemtamab,alate−stageoncologycandidate,toGMAB′sproprietarypipeline.GMABexpectspetosemtamabtodrivegrowth,withpotentialbillion−dollarsalescontributionsby2029.SharesofGenmabA/S(GMAB)haverallied21.98 billion in cash.The acquisition adds petosemtamab, a late-stage oncology candidate, to GMAB's proprietary pipeline.GMAB expects petosemtamab to drive growth, with potential billion-dollar sales contributions by 2029.Shares of Genmab A/S (GMAB) have rallied 21.9% in a month. The stock price rally was observed after the company signed a definitive agreement in late September to acquire Merus N.V. (MRUS) for 97 per share in c ...